Document Detail


Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.
MedLine Citation:
PMID:  21053035     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Cryoglobulinaemia associated with systemic vasculitis mediated by immune complexes is a rare combination. These immune complexes are composed of immunoglobulins and precipitate when exposed to cold temperature. Cryoglobulinaemic vasculitis, treated or untreated, may lead to substantial morbidity and even mortality. Novel targeted therapies may well provide new therapeutic options following or perhaps even prior to the classical cytotoxic therapies. Systemic B cell depletion with rituximab, a chimeric monoclonal antibody against CD20 antigen, is commonly applied in patients with non-Hodgkin's lymphoma or in refractory rheumatoid factor-positive rheumatoid arthritis. Since B cell clones are the source of cryoglobulins, therapeutic effectiveness of rituximab in cryoglobulinaemic vasculitis may be expected. We describe a 72-year-old woman with mixed cryoglobulinaemia type 2, who has successfully been treated with rituximab infusions after failing on prednisone and azathioprine. We reviewed the literature and found 142 cases of cryoglobulinaemic vasculitis, 138 mixed (type 2 or 3) and four, type 1. Rituximab was applied mostly after failure on other treatments. Significant reduction in levels of rheumatoid factor, cryoglobulins and IgM were reported after rituximab therapy. Of the total 142, cases 119 could be evaluated for the response on rituximab therapy, the other 23 cases only regarding side effects. Of the 119 evaluated patients, 71 (60%) had complete response; 28 (23%), partial response and 20 patients (17%), no response. Data were not blinded or placebo-controlled. Side effects were seen in 27 of the 142 patients. Occurrence of the side effects was associated with high baseline levels of cryoglobulins, with a high dose of rituximab infusion of 1,000 mg and with a high level of complement activation. Death was reported four times and was related with the disease.
Authors:
Freke Wink; Pieternella M Houtman; Tim L Th A Jansen
Related Documents :
7854605 - Using psychological tests for the early detection of neurotoxic effects of low level ma...
20732445 - The economics of priority review vouchers.
9988365 - Successful challenge with clozapine in a history of eosinophilia.
22752745 - Scuba divers' pulmonary oedema. a case report.
14752595 - Voiding dysfunction after surgery for stress incontinence: literature review and survey...
24757555 - Foreign body in the kidney: an unusual case and its management.
Publication Detail:
Type:  Journal Article     Date:  2010-10-31
Journal Detail:
Title:  Clinical rheumatology     Volume:  30     ISSN:  1434-9949     ISO Abbreviation:  Clin. Rheumatol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8211469     Medline TA:  Clin Rheumatol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  293-300     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Identification of novel 5-hydroxy-1H-indole-3-carboxylates with anti-HBV activities based on 3D QSAR...
Next Document:  Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women...